Disease & disorder
malignant glioma
MONDO:0100342
A grade III or grade IV glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
Loading mapped interventions…
MONDO disease family
Loading verified ontology relationships…
Recruiting studies by city
Loading research-site locations…
Trial status
Loading…
Trial phase
Loading…
Study start year
Loading…
Investigated drug interventions
Loading…
Clinical trials
15 shownImaging of Solid Tumors Using 18F-TRXNCT06942104 · 2025-07-03
RECRUITINGSafety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossNCT06810544 · 2025-03-24
RECRUITINGDabrafenib and/or Trametinib Rollover StudyNCT03340506 · 2018-01-26
RECRUITINGA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130 · 2022-11-30
ACTIVE_NOT_RECRUITINGOral AMXT 1501 Dicaprate in Combination With IV DFMONCT05500508 · 2022-11-29
TERMINATEDStudy of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsNCT04541225 · 2020-12-08
TERMINATED9-ING-41 in Patients With Advanced CancersNCT03678883 · 2019-01-04
ACTIVE_NOT_RECRUITINGSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)NCT03213678 · 2017-11-28
COMPLETEDVemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)NCT03220035 · 2017-11-08
COMPLETEDOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)NCT03233204 · 2017-09-14
COMPLETEDTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITINGStudy of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced CancersNCT02526017 · 2015-09-08
COMPLETEDEarly-Phase Safety of Proton Therapy EquipmentNCT02315989 · 2014-08-01
COMPLETEDAn Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.NCT01386580 · 2011-07-01
COMPLETEDA Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and AngiogenesisNCT00565721 · 2007-11-01
COMPLETEDDrugs being studied
Research locations
HoustonTexas, United States9New YorkNew York, United States9San FranciscoCalifornia, United States9DallasTexas, United States8Salt Lake CityUtah, United States8SeattleWashington, United States8BostonMassachusetts, United States7ChicagoIllinois, United States7Los AngelesCalifornia, United States7NashvilleTennessee, United States7PortlandOregon, United States7CincinnatiOhio, United States6
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.